Pilot Feasibility Governance Core drives biomarker discovery and patient-oriented rare-disease research
Official title: Pilot Feasibility Core
Funded at Henry Ford Health + Michigan State University Health Sciences · NIH-11453333 · Data updated 2026-11-12
A pilot-feasibility core supports biomarker discovery and improved diagnosis for polyamine-related disorders by connecting patients, families, clinicians, and researchers.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry Ford Health + Michigan State University Health Sciences NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project start | September 8, 2026 |
| Project end | June 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $56,566 |
| NIH project number | 1U54HD122910-01 |
| Project ID | NIH-11453333 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with polyaminopathies or related rare genetic disorders and their families who could benefit from improved diagnostics and potential future trials.
✕Less likely to help
Patients not affected by polyaminopathies or related disorders may not directly benefit from this core.
What this research studies
This grant funds a Pilot/Feasibility Governance Core that coordinates efforts to identify biomarkers, define disease phenotypes, and improve diagnosis and management of polyaminopathies. It emphasizes partnering with patient advocacy groups and clinicians to ensure patient needs guide project ideas, study design, and pilot trials. Teams will review and select pilot projects through a formal LOI process and provide resources to develop new diagnostic tests and companion studies. The work aims to translate basic discoveries into practical tools and clinical trials that could benefit people with rare genetic polyamine disorders.
Why it matters
Potential benefit: If successful, patients may gain faster and more accurate diagnoses and access to early-stage biomarker tests and pilot trials.
How similar studies have gone: Other centers have successfully used pilot/feasibility cores to develop biomarkers and diagnostics for rare diseases, though this field remains exploratory.
Where this research is happening
-
Henry Ford Health + Michigan State University Health Sciences
East Lansing, United States Active
Researchers
- Principal investigator: Vos, Miriam B. — Henry Ford Health + Michigan State University Health Sciences
- Study coordinator: Vos, Miriam B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.